Advertisement


Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).



Related Videos

Breast Cancer
Genomics/Genetics

Jennifer A. Ligibel, MD, on Gene Expression: Study Findings

Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version)

Aleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual...

Breast Cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatin...

Symptom Management
Breast Cancer

Jame Abraham, MD, on Hair Loss: SCALP Trial Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).

Breast Cancer

Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives

Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.

Advertisement

Advertisement



Advertisement